<?xml version="1.0"?>

<document>
	<title>Defective essential-fatty-acid metabolism in cystic fibrosis.</title>

	<author>Rivers-J-P.</author>
	<author>Hassam-A-G.</author>

	<source>Lancet. 1975 Oct 4. 2(7936). P 642-3. (REVIEW).</source>

	<abstract>Cystic fibrosis (C.F.) is characterised by low serum levels of
   essential fatty acids (E.F.A.). However, the fatty-acid pattern does
   not totally resemble that of dietary E.F.A. deficiency. The
   differences suggest a reduction in the desaturation of E.F.S. It is
   not known whether this defect is the primary lesion in C.F. or is the
   result of tissue damage in the disease. It is proposed that C.F.
   patients might have increased linoleic-acid requirements, and
   possibly specific requirements for its desaturation products.</abstract>

	<majorsubject>CYSTIC-FIBROSIS: me</majorsubject>
	<majorsubject>FATTY-ACIDS-ESSENTIAL: me</majorsubject>

	<minorsubject>ANIMAL</minorsubject>
	<minorsubject>DIETARY-FATS: me</minorsubject>
	<minorsubject>FATTY-ACID-DESATURASES: me</minorsubject>
	<minorsubject>FATTY-ACIDS-ESSENTIAL: df</minorsubject>
	<minorsubject>HUMAN</minorsubject>
	<minorsubject>PARENTERAL-FEEDING</minorsubject>
	<minorsubject>PHOSPHOLIPIDS: me</minorsubject>
	<minorsubject>REVIEW</minorsubject>

	<reference>001   ROSENLUND ML          NATURE                         251   719 974</reference>
	<reference>002   DODGE JA              BR MED J                         2   192 975</reference>
	<reference>003   BENNETT MJ            AM J CLIN NUTR                  20   415 967</reference>
	<reference>004   CAREN R               J CLIN ENDOCRINOL METAB         26   470 966</reference>
	<reference>005   KUO PT                J PEDIATR                       60   394 962</reference>
	<reference>006   KUO PT                J CLIN INVEST                   44  1924 965</reference>
	<reference>007   COLLINS FD            NUTR METAB                      13   150 971</reference>
	<reference>008   ELLIOTT RB            ARCH DIS CHILD                  50    76 975</reference>
	<reference>009   HOLMAN RT             PROG CHEM FATS OTHER LIPIDS      9   607 970</reference>
	<reference>010   WENE JD               J CLIN INVEST                   56   127 975</reference>
	<reference>013   BRENNER RR            MOL CELL BIOCHEM                 3    41 974</reference>
	<reference>014   BRENNER RR            LIPIDS                           6   567 971</reference>
	<reference>015   BRENNER RR            AM J PHYSIOL                   215    63 968</reference>
	<reference>016   NINNO RE              BIOCHIM BIOPHYS ACTA           360   124 974</reference>
	<reference>017   HUBBLE DV             CYSTIC FIBROSIS                       55 964</reference>

	<citation>1   HUBBARD VS            EUR J PEDIATR                  141    68 983</citation>
	<citation>2   FOGERTY AC            AM J CLIN NUTR                  39   201 984</citation>
	<citation>3   MCKENNA MC            J PEDIATR GASTROENTEROL NUTR     4    45 985</citation>
	<citation>4   FARRELL PM            PEDIATR RES                     19   104 985</citation>
	<citation>5   MISCHLER EH           PEDIATR RES                     20    36 986</citation>
	<citation>6   FRIEDMAN Z            PROG LIPID RES                  25   355 986</citation>
	<citation>7   CRAIGSCHMIDT MC       AM J CLIN NUTR                  44   816 986</citation>
	<citation>8   CARLSTEDTDUKE J       PROC NAT ACAD SCI USA           83  9202 986</citation>

</document>
